Peptide compounding regulation: how to read FDA status
Peptide regulatory claims change quickly and are often reduced to misleading labels such as “legal,” “banned,” or “Category 1.” This page explains the limits of those labels. It is educational material, not legal or medical advice, and it does not identify any peptide as available through WellSpry.
Category labels are not drug approvals
FDA's historical Category 1, 2, and 3 framework addressed nominated bulk substances under an interim compounding policy. A category label does not establish FDA approval, safety, effectiveness, a lawful product pathway, or suitability for an individual patient.
The review is substance-specific
FDA evaluates exact bulk substances and routes under statutory and policy criteria. A nomination, advisory-committee discussion, press statement, or proposed rule is not permission to market or compound a product. The current FDA list, policy, and applicable state law must be checked for the exact substance and formulation.
A prescription is not a blanket exception
A patient-specific prescription is only one part of the 503A framework. It does not by itself make use of a bulk substance lawful. Source, monograph or approved-drug-component status, the 503A Bulks List, current enforcement policy, pharmacy practice requirements, and state law can all matter.
Compounded drugs are not FDA-approved
Compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing in the same way as FDA-approved drugs. A pharmacy credential, certificate of analysis, or clinician prescription does not change that distinction or prove clinical benefit.
WellSpry's current boundary
WellSpry does not prescribe, sell, or facilitate peptide products and does not represent an active compounding-pharmacy relationship. Protocol Management enrollment and WellSpry-facilitated prescribing are temporarily unavailable while the clinical workflow completes review.
Verify current primary sources
Use FDA's current 503A Bulks List, interim-policy materials, safety communications, final rules, and applicable state requirements for the exact substance and route. Do not rely on this dated page, a clinic advertisement, or a social-media post for a current legal or clinical determination.